Curaleaf International, part of Curaleaf Holdings, said its Que Medical Inhalation Device is available in Australia after the country's Therapeutic Goods Administration registered it on 15 September 2026. The device, developed with Jupiter Research LLC, is listed as a Class IIb medical device on the Australian Register of Therapeutic Goods, and is the first device intended for the delivery of Cannabis Sativa L. extracts by patient inhalation to receive regulatory approval in Australia, the company said.
The device was also added on 17 September 2026 to the Web Assisted Notification of Devices database run by Medsafe, New Zealand's medicines and medical device regulator, which the company said makes it available to prescribers there. Vicki Partridge Pty Ltd is the sponsor in both Australia and New Zealand.
Mikael Sodergren, chief medical officer at Curaleaf International, said the registration means clinicians in Australia and New Zealand can for the first time prescribe a liquid cannabis inhalation device that has been formally approved and delivers standardised dosing in the same way as other medicines. Juan Martinez, the company's chief executive, said QMID is the first liquid cannabis inhalation device approved under both the EU and Australian medical device frameworks, and that Curaleaf intends to bring the same standard to more patients wherever the regulatory pathway allows, beginning with New Zealand.
The release says the devices used to inhale prescribed medicines have largely stayed outside the ARTG, while the medicines themselves are prescribed through the TGA's approved pathways. Prescribers and pharmacists have reported difficulty obtaining approvals for unregistered batteries, leaving some patients with their prescribed medicine but no compliant means of using it, and the regulator has repeatedly called for clinical justification where unapproved devices are used, according to the release. The company describes QMID as a controlled delivery system designed to support consistent dosing and comparable clinical data, with a compact design for discreet medical use and reusable hardware compatible only with approved cartridges.
QMID received certification as a Class IIa medical device under the European Medical Device Regulation 2017/745 in May 2025 and is now available in seven countries, the release says. More than one million patients have accessed treatment under Australia's prescribing framework since it was established in 2016, according to a market review referenced in the release.